Key Developments: Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

3:33pm EDT
Price Change (% chg)

$0.59 (+15.01%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Array BioPharma announces drug discovery collaboration agreement with Biogen Idec
Wednesday, 28 May 2014 09:00am EDT 

Array BioPharma Inc:Says collaboration agreement with Biogen Idec for discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.Biogen will be responsible for all aspects of clinical development and commercialization.Agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array.  Full Article

Array BioPharma Inc reaffirms FY 2014 EPS outlook; lowers FY 2014 revenue outlook; gives Q4 2014 outlook - Conference Call
Tuesday, 29 Apr 2014 09:00am EDT 

Array BioPharma Inc:Says there is no change to the FY 2014 guidance for loss per share, although the revenue guidance is several mln lower.Expect Q4 2014 revenue and loss per share to be pretty similar to Q3 2014.Reported revenue of $7.77 mln, EPS of $(0.20) in Q3 2014.FY 2014 revenue of $49.80 mln, EPS of $(0.69) - Thomson Reuters I/B/E/S.Q4 2014 revenue of $11.47 mln, EPS of $(0.21) - Thomson Reuters I/B/E/S.  Full Article

Oncothyreon Inc and Array BioPharma announce initiation of phase 1b trial of ONT-380 in combination with TDM-1 in patients with metastatic HER2+ breast cancer
Thursday, 20 Feb 2014 08:00am EST 

Oncothyreon Inc:Says the company and Array BioPharma Inc initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer.ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.The trial ( Identifier NCT01983501) is a dose-escalation study in up to 48 patients who have been previously treated with Herceptin (trastuzumab) and a taxane for metastatic breast cancer.Primary objective is to determine the maximum-tolerated and/or recommended Phase 2 dose (MTD/RP2D) of ONT-380 in combination with the approved dose of Kadcyla.Secondary objectives include an evaluation of the safety and preliminary anti-tumor activity of the combination.Following determination of the MTD/RP2D, the study includes an expansion arm at the MTD/RP2D as well as an optional second expansion arm in patients with central nervous system metastases.  Full Article

Array Biopharma Inc reaffirms FY 2014 guidance and gives Q3 2014 EPS guidance; revenue guidance below analysts' estimates - Conference Call
Tuesday, 4 Feb 2014 09:00am EST 

Array Biopharma Inc:Says no change to the FY 2014 guidance.Expects Q3 2014 revenue of $8 mln.Expects Q3 2014 loss per share of about $0.21.Q3 2014 revenue of $11.11 mln and EPS of $-0.20 - Thomson Reuters I/B/E/S.  Full Article

Array Biopharma Inc Announces Resignation Of President-Form 8-K
Thursday, 21 Nov 2013 08:05am EST 

Array Biopharma Inc reported in its Form 8-K that on November 15, 2013, Kevin Koch, Ph.D., resigned as President and Chief Science Officer of Array, effective November 29, 2013. Dr. Koch resigned to pursue other professional opportunities and his resignation did not arise from any disagreement on any matter relating to the Array’s operations, policies or practices.  Full Article

Array Biopharma Inc Raises FY 2014 Guidance - Conference Call
Thursday, 31 Oct 2013 09:00am EDT 

Array Biopharma Inc announced that for fiscal 2014, it expects revenue of $49 million and loss per share at $0.69, which is an improvement of $0.03 from last update.  Full Article

Array Biopharma Inc Issues FY 2014 Guidance-Conference Call
Thursday, 8 Aug 2013 09:00am EDT 

Array Biopharma Inc announced that for fiscal 2014, it expects revenue to be approximately $48 million and loss per share $0.72.  Full Article

Array Biopharma Inc Study Shows Asthma Candidate ARRY-502 Improves Lung Function-DJ
Tuesday, 23 Jul 2013 06:54am EDT 

Dow Jones reported that Array Biopharma Inc said a study showed its drug candidate, ARRY-502, improved a measure of lung function for people with mild to moderate persistent allergic asthma. Shares recently jumped 17% to $6.49 premarket as Array said results from a Phase 2 trial indicated ARRY-502 achieved the primary endpoint of significantly improving pre-bronchodilator forced expiratory volume in one second. ARRY-502 also was well tolerated with fewer side effects, when compared to a placebo. Secondary efficacy endpoints in the proof-of-concept study were also achieved, including reduced short-acting beta agonist use; asthma control; forced vital capacity improvement; symptom-free days during treatment; and improvement in rhinasthma and asthma quality of life questionnaires.  Full Article

Loxo Oncology, Inc And Array Biopharma Inc Announce License And Collaboration Agreement
Wednesday, 10 Jul 2013 08:00am EDT 

Loxo Oncology, Inc and Array Biopharma Inc announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. Under the terms of the agreement, Loxo will fund Array's preclinical research, providing access to Array's world-class discovery platform and scientists, and will be responsible for target selection and conducting clinical trials. Array is eligible to receive up to $434 million in payments and to receive royalties on sales of any resulting drugs. In further consideration of the rights granted to Loxo under the agreement, Array also received shares of stock in Loxo.  Full Article

Array Biopharma Inc Announces Positive Interim Results From Combination Trial Of Arry-520 With Kyprolis At The 2013 European Hematology Association Congress
Monday, 17 Jun 2013 08:00am EDT 

Array Biopharma Inc announced that interim results from an ongoing ARRY-520 clinical trial in multiple myeloma (MM) were presented at the 2013 Congress of the European Hematology Association in Stockholm, Sweden. Also at the meeting, Array presented updated information on a potential patient selection marker for ARRY-520. ARRY-520 is a selective, targeted inhibitor of KSP with a mechanism of action distinct from other drugs used to treat MM that continues to advance in clinical trials. Interim data from an ongoing combination trial of ARRY-520 with Kyprolis (carfilozomib) in patients with relapsed or refractory MM who are refractory or intolerant to Velcade (bortezomib) were reported. The combination has demonstrated early signals of activity with a disease control rate (complete response, partial response, minimal response or stable disease) of 82% and a clinical benefit rate (=minimal response) of 53%, including one complete response. In addition, the combination has been well tolerated with no unexpected hematologic toxicity and a manageable side effect profile. More than half of the patients enrolled remain on study, with patients in the current cohort receiving full doses of both drugs without reaching a maximum tolerated dose (MTD). Data on a potential patient selection marker was also presented from multiple studies of ARRY-520 in patients with relapsed and refractory multiple myeloma.  Full Article

MARKET PULSE-Microsoft, UBS, Zynga, Furiex, Array Biopharma, Gap

(For more market insights, including options activity, click on ; for the Day Ahead newsletter; for the Morning News Call newsletter, U.S. stocks rose on Tuesday, underpinned by a slew of sturdy corporate results, as the market regained its footing following its largest selloff in months a day earlier. The Dow Jones industrial average was up 0.32 percent at 15,422.57, the S&P 500 was up 0.50 percent at 1,750.54 and the Nasdaq Com

Search Stocks